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Abstract
Thalassemia is a significant health problem worldwide. There are two main classifica-
tions, α- and β-thalassemias, which are usually caused by the defective synthesis of the 
α-globin, and which are commonly caused by different mutations of the β-globin chain. 
Different hemoglobin mutations have been identified to date. Thalassemias can result in 
profound anemia from early life and, if not treated with regular blood transfusions, can 
lead to death in the first year. Prenatal diagnosis of thalassemia is the essential part of 
preventive medicine and is currently dependent on the use of invasive diagnostic tests 
within the first 2 months of pregnancy. These diagnostic techniques carry a small but sig-
nificant risk of fetal loss up to 1%. Molecular diagnostic methods have been developed for 
genotyping thalassemias based on PCR techniques and high-throughput technologies. 
Noninvasive tests using cell-free DNA (cfDNA) from a maternal blood sample is also an 
alternative method, thus eliminating the risk of miscarriage. This chapter summarizes 
the current invasive approaches and the noninvasive methods using cell-free fetal DNA 
as new molecular diagnostic methods for genotypic diagnosis of thalassemia in clinical 
practice. Prevention strategies that encompass carrier screening, genetic  counseling, and 
prenatal diagnosis are discussed.
Keywords: thalassemia, prenatal diagnosis, noninvasive test, cell-free DNA, molecular 
method
1. Introduction
Hemoglobin (Hb) is the oxygen carrier molecule in red blood cells. Each adult Hb molecule 
consists of four subunits: two α-globin and two β- (or β-like) globin chains. The α-globin gene 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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cluster maps near the telomere of the short arm of chromosome 16. The human β-globin spans 
a region of 70 kb on the short arm of chromosome 11 and contains 5 functional genes. Hb A 
is the predominant form of Hb molecule in an adult human [1–4]. The α-globin gene cluster 
undergoes one developmental “switch” but the β-gene cluster undergoes two “switches”. 
Transcription of the ε gene in the embryonic gene stage switches after the sixth week of gesta-
tion to the transcription of the two γ genes in the fetal liver and around the prenatal period, to 
the δ (minor adult) and β (major adult) genes (Figure 1). At 6 months after birth, hemoglobin 
F (HbF) constitutes less than 5% of the total hemoglobin and continues to fall, reaching the 
adult level of <1% at 2 years of age [4].
2. Hemoglobinopathies
Inherited hemoglobinopathies are large groups of autosomal recessive disorders [4]. There 
are more than 700 defects in globin genes that are found to be responsible for hemoglobin-
opathies [5]. The defective (+) or absent (0) production of one of the globin chains of the Hb 
tetramer causes autosomal recessive inherited disorders. The type of globin chain involved 
distinguishes α-, β-, and δ-thalassaemias [6]. The meaning of thalassemia comes from the 
Greek words thalassa; sea and aemia; anemia. It was observed that thalassemia is prevalent in 
areas in which malaria was seen or was endemic [7, 8].
Figure 1. Alpha beta globin gene cluster [4].
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The resulting imbalance in the ratio of α:β chains underlies the pathophysiology [3]. Both 
α-thalassemia and β-thalassemia, however, have a high frequency in many populations; 
although, β-thalassemia is more prevalent and more widely distributed. β-Thalassaemia is 
a member of an inherited hemoglobin disorder family that is characterized by reduction of 
β-globin chain synthesis [9]. The high frequency of thalassemia is due to the protective advan-
tage against malaria that it confers on carriers, analogous to the heterozygote advantage of 
sickle cell hemoglobin carriers. Thalassemias can result in profound anemia from early life 
and, if not treated with regular blood transfusions, can lead to death in the first year [7, 10].
3. Prevalence and classification of thalassemias
Thalassaemia was originally thought to be a disease limited to the Mediterranean region, in 
countries such as Greece, Italy, and Cyprus. There is a characteristic distribution of thalas-
semias in a band around the Old World—in the Mediterranean, the Middle East, and parts of 
Africa, India, and Asia [4, 5]. As a result, clinically important interactions may occur among 
different alleles of the same globin gene or among mutant alleles of different globin genes [6, 8]. 
The prevalence of β-thalassemia trait varies within the Mediterranean coastal regions in 
Turkey; Mediterranean (Adana 3.7%); Aegean (İzmir 4.8%); and Marmara (İstanbul 4.5%) [4] 
(Figure 2). In highly prevalent regions, an ideal and effective strategy to decrease the birth rate 
of thalassemia patients is to identify high-risk couples, who are both carriers, before pregnancy 
by screening (or carrier testing) and then perform a prenatal diagnosis during pregnancy [11].
Thalassemias are genetically classified according to the particular globin chains that are inef-
fectively synthesized into α, β, δβ, and εδβ thalassemias. α- and β-thalassemias are important 
in the public health view [12]. Different hemoglobin mutations have been identified to date, 
the majority being single nucleotide substitutions, deletions, or insertions of nucleotides lead-
ing to a frame shift; rarely does β-thalassaemia result from gene deletions. More than 250 
gene defects (more than 1150 mutations have been reported) have been described for different 
thalassemia phenotypes in different populations [11, 13]. β-Thalassemia have been described, 
and it has been found that the majority thalassemias can be caused by large deletions or by 
point mutations. α-thalassemia is often caused by large deletions for single (α+-thal) or both 
α-genes (α0-thal) (Table 1) [13].
Thalassemias exhibit a wide spectrum of phenotypes. Depending on the clinical severity, 
thalassemias are generally divided into three groups: (1) Thalassemia minor/trait: they are 
carriers who are often asymptomatic and do not need any treatment. (2) Thalassemia inter-
media (TI): they have moderate anemia and occasionally require red blood cell transfusion; in 
α-thalassemia, it is known as Hb H disease. (3) Thalassemia major (TM): they have severe ane-
mia and require transfusions for survival; in α-thalassemia, this clinical form was named Hb 
Bart’s hydrops fetalis. The fetus usually dies in utero or shortly after birth [11]. According to 
the degree of quantitative reduction in the synthesis of normal β-globin, β-thalassemia muta-
tions are classified into three groups: (1) β0-thalassemia mutation, which results in the absence 
of β-globin; (2) β+-thalassemia mutation, which severely reduces the output of β-globin; and 
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(3) β++-thalassemia mutation, also known as silent β-mutation, which mildly reduces the out-
put of β-globin (Figure 3) [11].
Clinical presentation for thalassemia carriers is varied from almost healthy to severe anemia 
requiring blood transfusions all life [14]. A practical way to prevent thalassemia is identifica-
tion of carrier couples; genetic counseling and offering prenatal diagnostic services for both 
carrier couples. Two carrier parents have a 25% chance of having an unaffected child, a 25% 
Figure 2. The distribution of common β-thalassemia mutations [7].
Table 1. The common deletions and mutations of thalassemias [13].
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chance of having an affected one, and a 50% risk of having a carrier child. Carriers can only be 
detected using laboratory methods. Laboratories should increase the diagnostic proficiency 
for prevention of this blood disorder [13, 15, 16].
In this review, we aim to provide an algorithm consisting of biochemical and molecular meth-
ods in the screening of thalassemia carriers and evaluate traditional and new prenatal diagno-
sis methods for the disorder.
4. Identification of carrier and diseased individuals with 
thalassemias
Carrier detection is a necessity in populations in which both α- and β-thalassemia are prev-
alent. For laboratory diagnosis of thalassemias, molecular diagnostic algorithms should be 
produced by screening centers (Figure 4). Combining blood hematology/biochemistry and 
clinical parameters with laboratory analysis, discussing the clinical results with physicians 
is important as the beginning step for carrier identification. The hematological information 
obtained from a complete blood count (CBC) is the first essential test for screening thalas-
semias (Figure 1). Specific mutations of hemoglobin will cause hematologic changes.
Hypochromic microcytic parameters and anemia is generally mild in α- or β-thalassemia carri-
ers. In cases with rare β-thalassemia, anemia can be intermediate or hemolytic and even severe 
because it is due to the reduced expression of the thalassemic gene and depends significantly 
on the degree of β-α imbalance [13].
Figure 3. Clinic classification and genotype-phenotype association of thalassemias [11].
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The first set of carrier detection procedure is the determination of main erythrocyte indices 
parameters such as the erythrocyte mean corpuscular volume (MCV), erythrocyte mean cor-
puscular hemoglobin (MCH) determination and also HbA2 quantitation. The current screening strategies for thalassaemia carriers are to identify individuals with clinically related mutations. 
Hypochromic microcytic anemia occurs in both iron deficiency anemia and thalassemias. A 
decrease in red blood cell count (RBC) and an increase in red cell distribution width (RDW) is 
accompanied by iron deficiency anemia. Increased RBC count and normal RDW values have 
been seen in hemoglobin disorders [13]. Serum ferritin levels, the golden standard, will usually be 
normal or elevated in β-thalassemia carriers but might also be borderline or low in α-thalassemia 
carriers [13]. Decreased hemoglobin (Hb) concentration and MCV levels, altered shape and size 
of the RBCs (anisopoikilocytosis) and existence of target cells are additional hematologic phe-
notypes observed in individuals with hemoglobin abnormalities. When compared to MCV, the 
MCH is a more stable parameter, and values of <27 pg and <25 pg have been recommended as 
alternative screening cut-offs for β-thalassemia and α°-thalassemia, respectively (Table 2) [17].
4.1. β-Thalassemia
Heterozygote β-thalassemia (β° or β+) is characterized by high red blood cell count, micro-
cytosis, hypochromia, increased HbA2 levels, and unbalanced α-globin/non-α-globin chain synthesis. Elevation of HbA2 (standard cut-off value is above 3.5%) is the most important characteristic in identifying heterozygote β-thalassemia [7, 19, 20]. A number of heterozy-
gotes for β-thalassemia may have normal or borderline HbA2 levels [21]. Some typical car-riers have mild β+ thalassemia mutation, i.e., IVSI-6 (T-C) mutation. The δ- and β-double 
heterozygotes exhibit normal HbA2 level, low MCV and MCH values. These double het-erozygote cases should be separated from the α-thalassemia carriers. Carriers of γδβ- and 
δβ-thalassemias HbA2 levels are also normal. δβ-thalassemias have specific elevated HbF 
Figure 4. The algorithim of screening and prenatal diagnosis for thalassemias.
Thalassemia and Other Hemolytic Anemias48
levels, which distinguish this group from the others [5, 12]. In the presence of a normal MCH, 
hereditary persistence of fetal hemoglobin (HPFH) should be considered. Another problem-
atic group difficult to identify is the silent β-thalassemia and the triple α-gene arrangement. 
In silent β-thalassemia, the MCV and MCH values are usually normal (i.e., β+-101 C > T muta-
tion). The value of HbA2 and HbF are also normal (Table 3) [21, 22].
4.2. α-Thalassemia
α-Thalassemia mutations are mostly gene deletions. To identify known inherited deletional 
α-thalassemia mutations, gap-PCR (polymerase chain reaction) is the most common method. 
A multiplex gap PCR targeting common α gene deletions in a population is most often used 
as the first step in α-thalassemia genotyping. The sequencing method detects non-deletion 
α+-thalassemia mutations. The five commonest α°-thalassaemia deletions can be diagnosed 
Traits Hb Ferritin MCV MCH RBC RCM
Iron deficiency ↓ ↓↓ ↓ ↓ ↓ APC, HY
β-Thalassemia trait ↓ ↑↑ ↓ ↓ ↑↑↑ APC, HY, TC
α-Thalassemia (-α/αα) ↓or N ↓N↑ ↓ ↓ ↑ Rare TC, HY
α-Thalassemia (--/αα) ↓ N↑ ↓ ↓ ↑↑ APC, HY, TC, rare IB
α-Thalassemia (-α/-α) ↓ N↑ ↓ ↓ ↑↑ APC,HY, TC
α-Thalassemia (--/-α) ↓ ↑↑↑ ↓ ↓ ↓ APC, HY, TC, IB
Hb, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; RBC, red blood cell; N, normal; 
APC, anisopoikilocytosis; HY, hypochromia; TC, target cells; IB, inclusion bodies [18].
Table 2. The most significant parameters observed from complete blood count, ferritin, MCV, MCH, RBC, and red cell 
morphology tests in the common traits at risk of intermediate or severe conditions for thalassemias.
Phenotype Genotype
Normal red cell indices • α- and β-thalassemia interaction
Normal HbA2 level • Iron deficiency
• Co-inheritance of δ- and β-thalassemmia
• Some mild β-thalassemmia mutations
• γδβ-thalassemia
Normal red cell indices and HbA2 level 
(silent)
• Silent β-thalassemmia mutations
• α-globin gene triplication
Severe heterozygote β-thalassemmia • Hyper unstable hemoglobin
• Co-inheritance of heterozygote β-thalassemmia and triple α-globin 
gene
Table 3. Interpretations to consider when the hematologic is consistent with atypical β-thalassaemia trait [7].
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by gap-PCR: the --SEA allele, the --MED and -(α)20.5 alleles; the --FIL allele, and finally the 
--THAI allele. The two commonest α+-thalassemia deletions are also diagnosed by gap-PCR: 
the -α3.7 and -α4.2 alleles. In our laboratory, the common deletions detected with gap-PCR 
are -α3.7, and -(α)20.5, --MED and -α4.2 (Figure 5).
5. Molecular methods
Blood count is not always consistent with typical β-thalassemia trait. Furthermore, there is 
no specific screening test for the clear identification of heterozygote α-thalassaemia. Only 
molecular DNA analysis could give certain results in rare mutations [23, 24].
Molecular methods for DNA analysis of hemoglobinopathies currently in use are based on PCR 
methods that can be used to detect the globin gene mutations. The PCR-based methods differ in 
identifying hemoglobin variants. Amplification refractory mutation system (ARMS), denatur-
ing gradient gel electrophoresis (DGGE), restriction endonuclease PCR (RE-PCR), real-time 
PCR, high-resolution melting analysis (HRM), sequencing analysis (Sanger), pyrosequencing, 
Figure 5. Applications of (A): ARMS-PCR, (B): RE-PCR for, (C): Gap-PCR, (D): HRMA and (E): sequencing analysis, (F): 
Detection unknown mutations using MLPA for deletional alpha, beta gene mutations (M: Mother, F: Father, C: Control, 
CVS: Chorionic villus sample).
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microarrays can be counted among these PCR-based detecting methods [19, 25]. To detect 
deletions, Southern blot analysis has been replaced by methods including gap-PCR, mul-
tiplex ligation-dependent probe amplification (MLPA), and array comparative genome 
hybridization (aCGH) [19]. Gene scanning methods such as HRM analysis are also useful for 
locating possible β-globin gene variants [26]. This technique allows the detection of muta-
tions between the primers used in the assay, which is in contrast to more localized tech-
niques such as hybridization based technologies or restriction enzyme-based assays [27]. In 
diagnostic use, for this method, it is mandatory to characterize any nucleotide variation by 
automated sequencing because they do not determine nucleotide changes. Small deletions 
can be detected by polyacrylamide gel electrophoresis of an amplified beta gene product. 
Polyacrylamide gel electrophoresis can be used to detect small deletions in an amplified β 
gene product. Gap-PCR and recently MLPA identifies larger deletions from the β-globin 
gene [10]. MLPA detects all common, rare, and novel forms of deletional α-thalassemia (in 
contrast to gap-PCR) and provides a reliable alternative screening method for the prenatal 
diagnosis of α°-thalassemia [28, 29, 30]. This technique can also identify triple and qua-
druple α-gene re-arrangements [31]. β°-Thalassemia, which is caused by small nucleotide 
deletions and some larger deletions which the whole β-globin gene removes, can be identi-
fied by gap-PCR (Hb Lepore, some δβ-thalassaemia deletions, and the HPFH1/2/3 deletion 
mutations, etc.).
5.1. Sequencing analysis
The parents’ DNA whose mutations were not found by classic PCR methods were analyzed 
by ABI 3130 automatic sequencer. The DNA of the cord blood samples were sequenced to 
confirm the cordosentesis results. BigDye Terminator v3.1 Cycle Sequencing kit (ABI) and 
primers that cover all the exons, introns,and exon-intron boundaries of the β-globin gene 
were used for sequencing analysis.
6. Prenatal diagnosis of thalassemias
Prenatal diagnosis created a new option to couples at risk of a major hemoglobinopathy and 
changed the perspective of screening and counseling for thalassemias [7]. The first step to pre-
vent thalassemia is prenatal diagnosis of these hematological disorders. Prenatal diagnosis 
for thalassemias is still carried out by traditional conventional methods such as amniocente-
sis, chorionic villus sampling (CVS), and cordocentesis. These conventional methods have a 
risk of fetal miscarriage risk around 1% [32].
6.1. Blood sampling from parents
Phenotype of parents should be performed by DNA analysis after whole blood count 
and electrophoresis. Hematology results should be sent to the molecular diagnostic labo-
ratory. Antenatal screening of parents should be performed before the first trimester of 
pregnancy [17].




Fetal DNA for analysis can be obtained by traditional invasive methods; amniocytes, CVS, 
and cordosentesis [4, 36].
6.2.1. Chorionic villus sampling
A fetal-derived tissue, genetically reflecting the fetus and easily accessible in the first trimester 
(up to 11 weeks) can be used for the prenatal diagnosis of hemoglobinopathies. High-quality 
DNA can be obtained from CVS material to perform DNA analysis. Maternal contamina-
tion is low, especially if careful microscopic dissection is performed to remove contaminating 
maternal tissues prior to DNA extraction and analysis.
6.2.2. Amniocentesis
This is the most commonly used method among invasive prenatal diagnostic methods. 
Amniotic fluid is the environment of life before the baby is born, and all secretions are in this 
atmosphere [33]. The prenatal diagnosis result based on an amniocentesis is available later in 
pregnancy compared to CVS, as amniocentesis is not usually performed earlier than the 15th 
week [19].
6.2.3. Fetal blood sampling
This sampling method can be used for molecular analysis, globin chain synthesis stud-
ies, or high-pressure liquid chromatography (HPLC). It can be useful in women at risk of 
α-thalassaemia hydrops fetalis. Fetal blood sampling is associated with a higher rate of mis-
carriage and results are available much later in pregnancy (after 18–20 weeks) [19].
6.2.4. HPLC analysis of cord blood
Cord blood is taken in ethylenediaminetetraacetic acid (EDTA) by an obstetrician at 
18–20 weeks of gestation. The hemograms are measured for all samples by using an automatic 
blood cell counter (Coulter T-890). HPLC analysis were studied from the prepared hemoly-
sate by Agilent 1100 using the thalassemia short program. The levels of HbA, HbF and Hb 
Barts, and HbS were estimated.
Molecular diagnostic methods that are based on PCR techniques (ARMS, RFLP, GAP-PCR, 
VNTR, etc.) and high-throughput technologies (Gene expression, HRMA, microarray, MLPA, 
NGS, etc.) are currently used in prenatal diagnosis. The molecular genetic tests for prenatal 
diagnosis within the first 2 months of pregnancy is necessary to prevent infants of carrier 
couples from being thalassemia [19].
6.3. Remove the contamination risk
Maternal cell contamination test is recommended in all prenatal samples to remove the risk 
of contamination of fetal DNA with maternal DNA. It is important to pay attention to all 
CVS and AF samples (with or without culture) may have maternal contamination. Maternal 
contamination should be ruled out after careful dissection of CVS from maternal tissue. 
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Polymorphic DNA sites in fetal and parental samples can be identified to monitor maternal 
contamination (Figure 6).
6.4. New diagnostic tests
The discovery of cell-free fetal DNA (cffDNA) in the maternal plasma give the chance to con-
duct noninvasive prenatal diagnosis (NIPD) during pregnancy [34]. Some encouraging clini-
cal noninvasive approaches to detect paternally inherited mutations such as the detection of 
fetal sex and RhD status have been improved successfully [35, 36].
Noninvasive tests using cell-free DNA (cfDNA) from a maternal blood sample is also an 
alternative method, thus eliminating the risk of miscarriage (Figure 7). Cell-free fetal DNA 
(cffDNA) constitutes approximately 10–15% of the total cfDNA and has been shown to repre-
sent the entire fetal genome [35].
6.5. Centrifugation
The noninvasive prenatal detection of paternal mutations in β-thalassemias is achievable 
using HRM analysis, and next generation sequencing of cell-free fetal DNA [36].
7. Conclusion
β-Thalassemia is an autosomal recessive disorder characterized by hemolytic anemia and 
micrositosis. It causes decreased synthesis of β-globin chain. This disorder influences 150 mil-
lion people in large parts of Asia, North Africa, and in the Mediterranean. A wide range of 
mutations occurs due to the effects of different cultures living together in Turkey. Genetic 
heterogenity is more in the southern part of Turkey than in other regions.
Figure 6. VNTR and STR analysis of a family for checking the maternal contamination in CVS. M: Mother, F: Father, 
CVS: Choronic Villus Sampling.
Figure 7. Noninvasive prenatal diagnosis using cfDNA from maternal plasma.
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Premarital screening and genetic counseling are essential for the prevention and control of 
thalassemia and hemoglobinopathies [9]. Today, prenatal diagnosis by chorionic villus sam-
pling is an accepted method to protect families having children with thalassemia major and 
to keep the disease under control. The mutation can be identified from samples obtained by 
chorionic villus sampling (CVS) and amniosentesis methods by classic polymerase chain reac-
tion (PCR).
The molecular diagnostic algorithms should be produced by genetic diagnosis centers for 
screening of the carriers and prenatal diagnosis of the couples both of whom carriage has 
been detected before pregnancy for protection against thalassemia.
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